Your browser is no longer supported. Please, upgrade your browser.
Vallon Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.20 Insider Own0.40% Shs Outstand6.81M Perf Week21.79%
Market Cap35.52M Forward P/E- EPS next Y-0.45 Insider Trans30.47% Shs Float3.20M Perf Month8.59%
Income-7.70M PEG- EPS next Q- Inst Own5.60% Short Float2.38% Perf Quarter-3.63%
Sales0.00M P/S- EPS this Y-38.10% Inst Trans-34.69% Short Ratio0.11 Perf Half Y32.75%
Book/sh1.28 P/B4.15 EPS next Y74.60% ROA-82.20% Target Price12.00 Perf Year-
Cash/sh1.38 P/C3.86 EPS next 5Y- ROE-105.30% 52W Range3.61 - 10.36 Perf YTD-29.39%
Dividend- P/FCF- EPS past 5Y- ROI435.30% 52W High-48.75% Beta-
Dividend %- Quick Ratio7.60 Sales past 5Y- Gross Margin- 52W Low47.09% ATR1.02
Employees2 Current Ratio7.60 Sales Q/Q- Oper. Margin- RSI (14)49.94 Volatility37.76% 19.07%
OptionableNo Debt/Eq0.02 EPS Q/Q-19.30% Profit Margin- Rel Volume0.87 Prev Close5.39
ShortableYes LT Debt/Eq0.01 Earnings- Payout- Avg Volume682.28K Price5.31
Recom2.00 SMA204.39% SMA50-10.36% SMA2000.15% Volume590,801 Change-1.48%
Nov-12-21 08:05AM  
Nov-11-21 08:05AM  
Nov-10-21 08:35AM  
Nov-04-21 02:30PM  
Nov-01-21 08:35AM  
Oct-26-21 03:23PM  
Oct-12-21 08:35AM  
Sep-14-21 08:05AM  
Aug-11-21 08:05AM  
Aug-10-21 08:05AM  
Jul-13-21 08:05AM  
May-30-21 04:48AM  
May-19-21 08:15AM  
May-13-21 09:15AM  
May-11-21 09:05AM  
May-07-21 08:05AM  
Apr-26-21 09:05AM  
Apr-13-21 08:05AM  
Mar-29-21 08:05AM  
Mar-03-21 08:35AM  
Feb-23-21 09:05AM  
Feb-12-21 03:30PM  
Feb-09-21 10:24PM  
Vallon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of prescription drugs for central nervous system disorders. The company develops abuse-deterrent amphetamine immediate-release, an abuse-deterrent oral formulation of immediate-release dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder and narcolepsy. It also develops ADMIR, an abuse deterrent formulation of Ritalin. Vallon Pharmaceuticals, Inc. was incorporated in 2018 and is based in Philadelphia, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kelly Leanne M.Chief Financial OfficerJun 04Buy4.081,5086,1536,250Jun 04 04:06 PM
Kelly Leanne M.Chief Financial OfficerJun 03Buy4.051,0854,3944,742Jun 04 04:06 PM
Kelly Leanne M.Chief Financial OfficerJun 02Buy4.003,65714,6283,657Jun 04 04:06 PM